Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance

Cancer Research

Volumn 69, Issue 1, 2009, Pages 203-211

  Simma, Olivia ^a   Zebedin, Eva ^a   Neugebauer, Nina ^a   Schellack, Carola ^a   Pilz, Andreas ^c   Chang Rodriguez, Souyet ^d   Lingnau, Karen ^e   Weisz, Eva ^a,f   Putz, Eva Maria ^a   Pickl, Winfried F ^b   Felzmann, Thomas ^d   Müller, Mathias ^g,h   Decker, Thomas ^c   Sexl, Veronika ^a   Stoiber, Dagmar ^a,f  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

^d ST ANNA CHILDREN S HOSPITAL   (Austria)

^e INTERCELL AG   (Austria)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^h University Center for Biomodels Austria VUW   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE 1; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 12P35; JANUS KINASE 3 INHIBITOR; OVALBUMIN; PROTEIN TYROSINE KINASE 2 INHIBITOR; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HUMAN; IN VIVO STUDY; LATENT PERIOD; LEUKEMIA CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; THYMOMA;

ANIMALS; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; FEMALE; IMMUNOLOGIC SURVEILLANCE; INTERFERON TYPE I; INTERFERON-GAMMA; INTERLEUKIN-12; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; THYMOMA; THYMUS NEOPLASMS; TYK2 KINASE;

EID: 58249103865     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1705     Document Type: Article

References (40)

1. Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol 2001;13:211-7.
2. Yamaoka K, Saharinen P, Pesu M, Holt VE III, Silvennoinen O, O'Shea JJ. The Janus kinases ( Jaks). Genome Biol 2004;5:253.
3. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002;109 Suppl:S121-31.
4. Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev 2004;4:97-105.
5. Garcia R, Bowman TL, Niu G, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001;20:2499-513.
6. Gao B, Shen X, Kunos G, et al. Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. FEBS Lett 2001;488:179-84.
7. Frank DA, Mahajan S, Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest 1997;100:3140-8.
8. Coffer PJ, Koenderman L, de Groot RP. The role of STATs in myeloid differentiation and leukemia. Oncogene 2000;19:2511-22.
9. Gouilleux-Gruart V, Debierre-Grockiego F, Gouilleux F, et al. Activated Stat related transcription factors in acute leukemia. Leuk Lymphoma 1997;28:83-8.
10. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007;282:20059-63.
11. Karaghiosoff M, Neubauer H, Lassnig C, et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 2000;13:549-60.
12. Shimoda K, Kato K, Aoki K, et al. Tyk2 plays a restricted role in IFNα signaling, although it is required for IL-12-mediated T cell function. Immunity 2000;13:561-71.
13. Strobl B, Bubic I, Bruns U, et al. Novel functions of tyrosine kinase 2 in the antiviral defense against murine cytomegalovirus. J Immunol 2005;175:4000-8.
14. Schleicher U, Mattner J, Blos M, et al. Control of Leishmania major in the absence of Tyk2 kinase. Eur J Immunol 2004;34:519-29.
15. + T cells producing IFN-γ. Eur J Immunol 2006;36:3060-70.
16. Karaghiosoff M, Steinborn R, Kovarik P, et al. Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat Immunol 2003;4:471-7.
17. Seto Y, Nakajima H, Suto A, et al. Enhanced Th2 cell-mediated allergic inflammation in Tyk2-deficient mice. J Immunol 2003;170:1077-83.
18. Stoiber D, Kovacic B, Schuster C, et al. TYK2 is a key regulator of the surveillance of B lymphoid tumors. J Clin Invest 2004;114:1650-8.
19. Ruhe JE, Streit S, Hart S, et al. Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res 2007;67:11368-76.
20. Kaminker JS, Zhang Y, Waugh A, et al. Distinguishing cancer-associated missense mutations from common polymorphisms. Cancer Res 2007;67:465-73.
21. Tomasson MH, Xiang Z, Walgren R, et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 2008;111:4797-808.
22. Song XC, Fu G, Yang X, Jiang Z, Wang Y, Zhou GW. Protein expression profiling of breast cancer cells by dissociable antibody microarray (DAMA) staining. Mol Cell Proteomics 2008;7:163-9.
23. Ide H, Nakagawa T, Terado Y, Kamiyama Y, Muto S, Horie S. Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells. Biochem Biophys Res Commun 2008;369:292-6.
24. Schuster C, Muller M, Freissmuth M, Sexl V, Stoiber D. Commentary on H. Ide et al., "Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells". Biochem Biophys Res Commun 2008;366:869-70.
25. Minegishi Y, Saito M, Morio T, et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 2006;25:745-55.
26. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007;117:1137-46.
27. Shinkai Y, Rathbun G, Lam KP, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992;68:855-67.
28. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon-γ genes. Science (New York) 1993;259:1739-42.
29. Muller U, Steinhoff U, Reis LF, et al. Functional role of type I and type II interferons in antiviral defense. Science (New York) 1994;264:1918-21.
30. Mattner F, Magram J, Ferrante J, et al. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol 1996;26:1553-9.
31. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994;76:17-27.
32. Derdak SV, Kueng HJ, Leb VM, et al. Direct stimulation of T lymphocytes by immunosomes: virus-like particles decorated with T cell receptor/CD3 ligands plus costimulatory molecules. Proc Natl Acad Sci U S A 2006;103:13144-9.
33. Hollenbaugh JA, Dutton RW. IFN-γ regulates donor CD8 T cell expansion, migration, and leads to apoptosis of cells of a solid tumor. J Immunol 2006;177:3004-11.
34. Chung SW, Cohen EP, Kim TS. Generation of tumor-specific cytotoxic T lymphocyte and prolongation of the survival of tumor-bearing mice using interleukin-18-secreting fibroblasts loaded with an epitope peptide. Vaccine 2004;22:2547-57.
35. Chamoto K, Wakita D, Narita Y, et al. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy. Cancer Res 2006;66:1809-17.
36. Ikeda H, Old LJ, Schreiber RD. The roles of IFNγ in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002;13:95-109.
37. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-46.
38. Wakita D, Chamoto K, Zhang Y, et al. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen. Int Immunol 2006;18:425-34.
39. Dunn GP, Bruce AT, Sheehan KC, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005;6:722-9.
40. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science (New York) 2003;302:875-8.